{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:00:12Z","timestamp":1649091612725},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1157\/13115024","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T22:09:01Z","timestamp":1208902141000},"page":"30-34","source":"Crossref","is-referenced-by-count":0,"title":["F\u00e1rmacos antialdoster\u00f3nicos: su papel en la insuficiencia card\u00edaca"],"prefix":"10.1016","volume":"130","author":[{"given":"Enrique","family":"Galve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13115024_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1157\/13115024_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","article-title":"Chronic administration of aldosterone depresses baroreceptor reflex function in the dog","volume":"24","author":"Wang","year":"1994","journal-title":"Hypertension"},{"key":"10.1157\/13115024_bb0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1157\/13115024_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1157\/13115024_bb0025","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0040","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1157\/13115024_bb0045","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/0140-6736(93)92930-R","article-title":"Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group","volume":"342","author":"Waagstein","year":"1993","journal-title":"Lancet"},{"key":"10.1157\/13115024_bb0050","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(79)92010-5","article-title":"Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade","volume":"1","author":"Swedberg","year":"1979","journal-title":"Lancet"},{"key":"10.1157\/13115024_bb0055","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic Heart failure: Metoprolol CR\/XL Randomized Intervention Trial in Congestive Herat Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1157\/13115024_bb0060","first-page":"2682","article-title":"A new drug against heart failure was retracted after an alarm about increased mortality","volume":"90","author":"Lennholm","year":"1993","journal-title":"Lakartidningen"},{"key":"10.1157\/13115024_bb0065","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ejheart.2004.09.006","article-title":"Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction","volume":"7","author":"Galve","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1157\/13115024_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u00abEscape\u00ab\u00bb of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1157\/13115024_bb0075","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1157\/13115024_bb0080","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1157\/13115024_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0090","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1157\/13115024_bb0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/eurheartj\/ehi023","article-title":"Spironolactone improves lung diffusion in chronic heart failure","volume":"26","author":"Agostoni","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1157\/13115024_bb0100","first-page":"650","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1157\/13115024_bb0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction: Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1157\/13115024_bb0110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1157\/13115024_bb0120","doi-asserted-by":"crossref","unstructured":"Pitt B, Gheorghiade M, Zannad F, Anderson JL, Van Veldhuisen DJ, Parkhomenko A, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction \u2264 30%. Eur J Heart Fail 2006; [Epub en prensa].","DOI":"10.1016\/j.ejheart.2005.11.008"},{"key":"10.1157\/13115024_bb0125","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"key":"10.1157\/13115024_bb0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejheart.2007.04.004","article-title":"Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet","volume":"9","author":"Cleland","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1157\/13115024_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0140","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"10.1157\/13115024_bb0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1157\/13115024_bb0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1157\/13115024_bb0160","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1157\/13115024_bb0165","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1157\/13115024_bb0170","first-page":"e154","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"10.1157\/13115024_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/clc.4960290103","article-title":"Hospital protocols and evidence-based therapies: the importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure","volume":"29","author":"Fonarow","year":"2006","journal-title":"Clin Cardiol"},{"key":"10.1157\/13115024_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00129784-200707010-00007","article-title":"Aldosterone antagonists: the most underutilized class of heart failure medications","volume":"7","author":"Guglin","year":"2007","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308713368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308713368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T16:43:32Z","timestamp":1557506612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775308713368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0025775308713368"],"URL":"https:\/\/doi.org\/10.1157\/13115024","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}